CorMedix Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
CRMD$5.37-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
1.Financial Statements. The following consolidated financial statements of CorMedix Inc. are filed as part of this Annual Report on Form 10-K:
| Report of Independent Registered Public Accounting Firm (PCAOB ID # 199) | F-2 |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID # 688) | F-4 |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Operations and Comprehensive Income (Loss) Years Ended December 31, 2025 and 2024 | F-6 |
| Consolidated Statements of Changes in Stockholders’ Equity Years Ended December 31, 2025 and 2024 | F-7 |
| Consolidated Statements of Cash Flows Years Ended December 31, 2025 and 2024 | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
- Financial Statement Schedules. The Financial Statement Schedules have been omitted because of the absence of conditions under which they are required or because the required information, where material, is shown in the financial statements or notes thereto.
3.Exhibit Index. The following is a list of exhibits filed as part of this Annual Report on Form 10-K:
| Exhibit Number · Description of Document · Registrant’s Form · Dated · Exhibit Number · Filed or Furnished Herewith | ||||
|---|---|---|---|---|
| 1.1 | At-the-Market Issuance Sales Agreement, dated August 12, 2021, by and among CorMedix Inc., Truist Securities, Inc. and JMP Securities LLC | 8-K | 08/12/2021 | 1.1 |
| 2.1 | Agreement and Plan of Merger, dated as of August 7, 2025, by and among CorMedix Inc., Melinta Therapeutics, LLC, Coriander BidCo LLC and Deerfield Private Design Fund IV, L.P., solely in its capacity as representative, agent and attorney-in-fact of the Company Members | 8-K | 08/07/2025 | 2.1 |
| 3.1 | Form of Amended and Restated Certificate of Incorporation | S-1/A | 3/01/2010 | 3.3 |
| 3.2 | Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated February 24, 2010 | S-1/A | 3/19/2010 | 3.5 |
| 3.3 | Second Amended and Restated Bylaws as amended October 8, 2020 | 8-K | 10/14/2020 | 3.1 |
| 3.4 | Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated December 3, 2012 | 10-K | 3/27/2013 | 3.3 |
| 3.5 | Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated August 9, 2017 | 8-K | 8/10/2017 | 3.1 |
| 3.6 | Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated March 25, 2019 | 8-K | 3/25/2019 | 3.1 |
| 3.7 | Amended and Restated Certificate of Designation of Series C-3 Non-Voting Convertible Preferred Stock of CorMedix Inc., filed with the Delaware Secretary of State on September 15, 2014 | 8-K | 9/16/2014 | 3.16 |
| Exhibit Number | Description of Document | Registrant’s Form | Dated | Exhibit Number | Filed or Furnished Herewith |
|---|---|---|---|---|---|
| 3.8 | Third Amended and Restated Certificate of Designation of the Series E Convertible Preferred Stock of CorMedix Inc., dated August 6, 2025. | 10-Q | 8/07/2025 | 3.1 | |
| 4.1 | Specimen of Common Stock Certificate | S-1/A | 3/19/2010 | 4.1 | |
| 4.2 | Description of Capital Stock of CorMedix Inc. | X | |||
| 4.3 | Form of Indenture, to be entered into by and between CorMedix Inc. and U.S. Bank Trust Company, National Association | 8-K | 08/07/2025 | 4.1 | |
| 4.4 | Form of 4.00% Convertible Senior Notes due 2030 of CorMedix Inc. (included in Exhibit 4.1) | 8-K | 08/07/2025 | 4.2 | |
| 10.1* | License and Assignment Agreement, dated as of January 30, 2008, between CorMedix Inc. and ND Partners LLC | S-1/A | 12/31/2009 | 10.5 | |
| 10.2+ | Form of Indemnification Agreement between CorMedix Inc. and each of its directors and executive officers | 10-Q | 5/15/2023 | 10.1 | |
| 10.3 | Backstop Agreement, dated November 9, 2017, between CorMedix Inc. and the investor named therein | 8-K | 11/13/2017 | 10.2 | |
| 10.4 | Form of Registration Rights Agreement, dated November 9, 2017, by and between CorMedix Inc. and the investor named therein | 8-K | 11/13/2017 | 10.3 | |
| 10.5 | Amendment No. 1, dated as of December 11, 2017, to Registration Rights Agreement, dated November 9, 2017, by and between CorMedix Inc. and the investor named therein | 8-K | 12/11/2017 | 10.1 | |
| 10.6 | Securities Purchase Agreement, dated December 31, 2018, between CorMedix Inc. and the investor named therein | 8-K | 1/03/2019 | 10.1 | |
| 10.7 | Securities Exchange Agreement, dated August 14, 2019, by and among CorMedix Inc. and the Existing Security holders listed on the Schedule of Holders thereto | 8-K | 8/15/2019 | 10.1 | |
| 10.8 | Amended and Restated Registration Rights Agreement, dated as of September 6, 2019, by and among CorMedix Inc. and Manchester Securities Corp., and Elliot International, L.P. and Elliot Associates, L.P. | 8-K | 9/11/2019 | 10.1 | |
| 10.9+ | Amended and Restated 2019 Omnibus Stock Incentive Plan | S-8 | 10/26/2022 | 99.1 | |
| 10.10+ | Amendment No. 1 to the Amended and Restated CorMedix Inc. 2019 Omnibus Stock Incentive Plan | 8-K | 11/21/2024 | 10.1 | |
| Exhibit Number | Description of Document | Registrant’s Form | Dated | Exhibit Number | Filed or Furnished Herewith |
|---|---|---|---|---|---|
| 10.11+ | Amendment No. 2 to the Amended and Restated CorMedix Inc. 2019 Omnibus Stock Incentive Plan. | 10-Q | 11/12/2025 | 10.5 | |
| 10.12+ | 2021 Executive Bonus Plan | 8-K | 12/23/2021 | 10.1 | |
| 10.13 | Contingent Payment Agreement, dated August 29, 2025, by and among Deerfield Private Design Fund IV, L.P., Deerfield Private Design Fund III, L.P., CorMedix Inc., a Delaware corporation, Melinta Therapeutics, LLC, and Deerfield Private Design Fund IV, L.P., a Delaware limited partnership, solely in its capacity as representative | 8-K | 9/2/2025 | 10.1 | |
| 10.14 | Registration Rights Agreement, dated August 29, 2025, by and among CorMedix Inc., Deerfield Private Design Fund IV, L.P., Deerfield Private Design Fund III, L.P. and each other Holder (as defined in the Registration Rights Agreement) | 8-K | 9/2/2025 | 10.2 | |
| 10.15+ | Executive Employment Agreement, dated December 12, 2023, between CorMedix Inc. and Beth Zelnick Kaufman. | 10-K | 3/25/2025 | 10.16 | |
| 10.16+ | Employment Agreement by and between CorMedix, Inc. and Susan Blum, dated August 28, 2025 | 8-K | 9/2/2025 | 10.3 | |
| 10.17+ | Employment Agreement by and between CorMedix, Inc. and Elizabeth Hurlburt, dated August 29, 2025 | 8-K | 9/2/2025 | 10.4 | |
| 10.18+ | Employment Agreement by and between CorMedix, Inc. and Matthew David, dated August 31, 2025 | 8-K | 9/2/2025 | 10.5 | |
| 10.19+ | Amended and Restated Employment Agreement by and between CorMedix, Inc. and Joseph Todisco, dated January 5, 2026. | X | |||
| 19.1 | Insider Trading Policies and Procedures | X | |||
| 21.1 | List of Subsidiaries | X | |||
| 23.1 | Consent of Independent Registered Public Accounting Firm (CBIZ CPAs P.C) | X | |||
| 23.2 | Consent of Independent Registered Public Accounting Firm (Marcum LLP) | X | |||
| 31.1 | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||
| 32.1*** | Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | |||
| 32.2*** | Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | |||
| 97.1 | Board Policy on Recouping Incentive Compensation | 10-K | 3/12/2024 | 97.1 | |
| 101.INS | Inline XBRL Instance Document | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | X | |||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | X | |||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | X | |||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | X | |||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | X | |||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | X | |||
| * | Confidential treatment has been granted for portions of this document. The omitted portions of this document have been filed separately with the SEC. |
|---|---|
| ** | Portions of the exhibit have been omitted in reliance on Item 601(b)(10)(iv) of Regulation S-K. |
| *** | These certifications are furnished. |
| + | Indicates management contract or compensation plan. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.